BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.